Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ZoomInfo Technologies (GTM) heads into the final days of September with short sellers trimming positions but the fundamental story remaining deeply contested, as a stock down 14% over the past month absorbs the gap between its $3.63 price and a Street that still cannot agree on a floor.
Short interest has dropped sharply from its late-August peak, falling from roughly 43.7 million shares to 35.2 million, a decline of about 19% over the month. At 11.3% of the free float, the position is still meaningfully elevated, but the direction of travel is clear: bears have been covering. The lending market confirms there is no shortage of supply to borrow against. Availability runs at 1,174%, meaning there are roughly 11 shares available for every share already borrowed, comfortably above the 52-week low of 278%. Cost to borrow has also eased, falling another 15% on the week to 0.47%, well below the levels that would signal any squeeze pressure. Options positioning is muted too. The put/call ratio at 1.08 is actually slightly below its 20-day average of 1.15, a z-score of negative 0.72, meaning options traders are not adding fresh downside protection even as the stock continues to drift lower. The overall picture from positioning is that the most aggressive bears have stepped back, but no clear buyers have emerged to fill the gap.
The Street tells a bleak story. The analyst consensus is weighted toward neutral and sell. Following the August earnings print, Citigroup maintained its Sell rating and nudged its target to $2.50, a level that implies further downside from the current price. UBS and DA Davidson both held Neutral but trimmed targets to $4.50. Wells Fargo kept Underweight with a $3.00 target. Only Stifel moved in the opposite direction, raising its Hold target to $4.00. The mean target of $4.58 implies modest upside from $3.63, but the distribution of ratings makes that average a weak signal. The bear case is well-articulated: net retention has fallen to 89%, the count of customers with more than $100K in ARR declined sequentially, and management cut the full-year 2026 revenue guide to $1.195 billion, implying a 4% decline year on year. The balance sheet carries roughly $1.32 billion of debt against $175 million in cash, leaving little room for error. Bulls point to calculated billings of $311.6 million, 1,900 customers above the $100K ACV threshold, and a restructuring program targeting $60 million in annual run-rate savings. The EV/EBITDA multiple of 4.9x and a P/E of 3.2x reflect just how low expectations have already been reset, but a cheap multiple is not a catalyst on its own.
One register entry is worth flagging on the ownership side. Jennifer Stier has an active Schedule 13D on file, with the most recent amendment raising her disclosed stake to 6.9% of the class, up from 6.7%, filed in June 2026. A 13D filing signals activist or at least engaged intent rather than passive ownership, and the position has been filed three times since August 2025. As always with 13D/G disclosures, stakes are as-last-disclosed around the 5% threshold, and a holder below that level may not file again. Separately, BlackRock raised its disclosed stake to 13.1% from 10.6% in its July 2026 amendment, and AQR Capital crossed the 5% threshold for the first time in August with a fresh 13G filing at 5.54%. Glenview Capital, which had held 5.35%, filed to report its position had fallen to zero in August. The net effect is that passive index and quant money is building even as a notable active manager has fully exited.
Retail attention on ZoomInfo is at a multi-month low. The Wikipedia-derived attention signal, which measures engagement against the company's own 90-day history across English Wikipedia views and ORTEX stock page visitors, came in at a z-score of negative 2.4 as of mid-September. That is not a revenue signal, but it does suggest the stock has slipped well off the radar of retail market participants.
The next earnings print is scheduled for 2 November, 33 days out. The two most recent quarterly releases moved the stock sharply higher on the day, 14.4% and 9.7% respectively, though both followed significantly lowered expectations. With the stock down 14% over the past month and short sellers having already covered a large portion of their positions, the debate ahead of November is less about whether ZoomInfo is cheap on reported numbers and more about whether the consumption-based pricing transition and the AI competitive threat have yet to fully show up in the billings line.
See the live data behind this article on ORTEX.
Open GTM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
